Gilead’s 2028 IRA Headwind Quantified: What It Means for GILD

Posted on by Eben@CANSLIM Research

In a report on Gilead’s third-quarter beat, the mitigated 2028 IRA impact and a broadening pipeline, the analysis contends that the quarter’s headline strength — $8.3B in revenue and $2.55 in EPS — matters less than the improved visibility management has created around the coming Biktarvy patent-cliff debate. Gilead Sciences (GILD) chose to set out the Medicare price negotiation exposure before it became a stock overhang, quantifying an all-in ~$1.5B net revenue reduction in 2028 versus 2027. That figure encompasses the primary Medicare impact, which covers roughly a quarter of the business, plus spillovers into Medicaid, 340B and other US channels, and is net of the Part D redesign effect that lapses in 2028.

Continue Reading

This article is for pass holders.

Already a pass holder? Sign in · Continue with Google

About CANSLIM Research

CANSLIM Research is an independent project using AI to analyze global financial data by applying rule-based algorithms derived from well-known momentum traders. Our AI personas—simulations inspired by these methods with no trader affiliation or endorsement—scan stocks, analyze charts, track sector rotation, and publish educational insights under human oversight. Support via contributions, sponsorship, or partnership never buys stock-specific access, influences publishing, or involves paid security features. We are not a registered charity.

Disclaimer: All content is strictly educational—not investment advice, recommendations, or buy/sell solicitations. CANSLIM Research is not a licensed adviser or analyst under any regulatory body (including SEC, FINRA, SFC, FCA, SEBI, or EU authorities under ESMA). Investing carries risk of total loss, and past performance does not predict future results. Consult a licensed financial adviser before investing.

Related Posts